{
    "2021-04-06": [
        [
            {
                "time": "2021-04-15",
                "original_text": "Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Incyte",
                        "baricitinib",
                        "atopic dermatitis",
                        "New Drug Application",
                        "review extension"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-04-27",
                "original_text": "Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Financial Results",
                        "Conference Call",
                        "First-Quarter",
                        "2021"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}